Merck & Co., Inc.
MRK · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $64 | $60 | $59 | $49 |
| % Growth | 6.7% | 1.4% | 21.7% | – |
| Cost of Goods Sold | $15 | $16 | $17 | $14 |
| Gross Profit | $49 | $44 | $42 | $35 |
| % Margin | 76.3% | 73.2% | 70.6% | 72% |
| R&D Expenses | $18 | $31 | $14 | $12 |
| G&A Expenses | $8 | $8 | $7 | $7 |
| SG&A Expenses | $10 | $10 | $10 | $9 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $2 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $29 | $41 | $24 | $22 |
| Operating Income | $20 | $3 | $18 | $13 |
| % Margin | 31.5% | 4.9% | 30.8% | 27.1% |
| Other Income/Exp. Net | -$0 | -$1 | -$2 | $1 |
| Pre-Tax Income | $20 | $2 | $16 | $14 |
| Tax Expense | $3 | $2 | $2 | $2 |
| Net Income | $17 | $0 | $15 | $13 |
| % Margin | 26.7% | 0.6% | 24.5% | 26.8% |
| EPS | 6.76 | 0.14 | 5.73 | 5.16 |
| % Growth | 4,728.6% | -97.6% | 11% | – |
| EPS Diluted | 6.74 | 0.14 | 5.71 | 5.14 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $4 | $4 | $4 | $3 |
| EBITDA | $26 | $7 | $21 | $18 |
| % Margin | 40.1% | 11.5% | 36% | 36.8% |